💡 Step 1: Understand the Basis – ICH Q1B and TGA’s Position

The TGA follows the ICH Q1B guideline for photostability testing, requiring both:

• ☀️ Option 1: A combination of cool white fluorescent and near-UV light sources
• ☀️ Option 2: A comprehensive light source that meets both spectrum requirements

Minimum exposure:

• 💡 1.2 million lux hours (visible light)
• 💡 200 watt hours/m² (UV light)

The TGA expects studies to be robust, reproducible, and applicable to both API and drug product under actual packaging conditions.

📑 Step 2: Conduct Forced Degradation Under Light Stress

Begin with stress testing of the Active Pharmaceutical Ingredient (API) to determine its sensitivity to light. Document degradation pathways, especially formation of photodegradants. Include:

• 💡 Chemical structure analysis of impurities
• 💡 Quantification using stability-indicating analytical methods
• 💡 Identification of potential toxicological risks

Include this data in Module 3.2.S of your regulatory submission to demonstrate risk awareness early in development.

🗄 Step 3: Test the Drug Product in Final Packaging

The TGA specifically requires photostability testing on the drug product in:

• ✅ Immediate container (e.g., blister, bottle)
• ✅ Market pack (with labeling and secondary carton)

Run parallel tests using fully exposed and protected samples to assess the effectiveness of the packaging against light exposure. The TGA assesses packaging protection as part of product shelf life justification.

📊 Step 4: Use Validated Analytical Methods

All photostability results must be generated using validated stability-indicating methods. These should be capable of detecting both degradation products and subtle changes in potency, color, or dissolution. Your validation report must include:

• 🔎 Linearity, accuracy, precision, specificity, LOD/LOQ
• 🔎 Robustness under photo-induced changes

Include method validation reports in Module 3.2.S.4 and 3.2.P.5 of your eCTD submission to the TGA.

📁 Step 5: Document Protocol and Results Clearly

A TGA-compliant photostability report must include:

• 📄 Study protocol with justification for test conditions
• 📄 Description of test articles, light sources, and equipment calibration
• 📄 Tables of test results, degradation profiles, and plots
• 📄 Conclusions and impact on shelf life and storage conditions

Results that show no significant degradation may justify labeling the product as “store below 30°C, protect from light.”

📤 Step 6: TGA Labeling and Shelf Life Impact

The outcome of photostability testing directly influences the product label and packaging statements. TGA-approved labels may require one of the following based on results:

• 📑 “Protect from light” (if degradation occurs under tested conditions)
• 📑 “Store below 25°C and protect from light” (for light-sensitive and temperature-sensitive products)
• 📑 No light-specific storage condition (if no significant change is observed)

Make sure these instructions align across your Consumer Medicine Information (CMI), Product Information (PI), and container label files submitted to the TGA.

🔗 Internal and External Submission Considerations

When submitting photostability data to the TGA, also consider harmonizing these aspects with your global submissions to USFDA or EMA to avoid inconsistencies. Additionally, align your testing approach with internal process validation programs to ensure long-term stability confidence.

🔎 Common Deficiencies Observed by the TGA

Based on past TGA deficiency letters, applicants frequently face objections due to:

• ❌ Use of non-validated light sources
• ❌ Testing only in API form, not final packaging
• ❌ Missing analytical method validation data
• ❌ Incomplete or misaligned labeling statements

To avoid rejection or lengthy clarification rounds, ensure your photostability documentation is complete, methodologically sound, and supported by scientific rationale.

🏆 Final Takeaway: Proactive Compliance = Regulatory Success

Photostability studies under TGA expectations go beyond checkbox compliance—they demand a systematic approach rooted in ICH Q1B principles, but interpreted through Australia’s unique regulatory lens. Pharma companies looking to commercialize in Australia must take a proactive, documentation-heavy route to ensure success.

• 🚀 Perform early forced degradation on API and drug product
• 🚀 Evaluate photostability in final packaging
• 🚀 Validate methods and support all claims with data
• 🚀 Align labels and documentation for end-to-end regulatory traceability